Bavarian Nordic (BVNRY)
(Delayed Data from OTC)
$12.20 USD
-0.10 (-0.79%)
Updated Aug 6, 2025 02:03 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BVNRY 12.20 -0.10(-0.79%)
Will BVNRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BVNRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BVNRY
Is Bavarian Nordic (BVNRY) Stock Undervalued Right Now?
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?
BVNRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Bavarian Nordic (BVNRY) a Great Value Stock Right Now?
Should Value Investors Buy Bavarian Nordic (BVNRY) Stock?
Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for BVNRY
Protean Funds Scandinavia AB July 2025 Partner Letter
Bavarian Nordic (BVNRY) Shares Surge After Takeover Talks Announcement
Bavarian Nordic climbs after buyout offer
CSL to replace Bavarian Nordic in Valneva’s vaccine deal for Germany
Bavarian Nordic sells its Priority Review Voucher for $160M